Phillips Courtney Sells 2,012 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Phillips Courtney sold 2,012 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $52,332.12. Following the transaction, the insider owned 7,007 shares in the company, valued at approximately $182,252.07. This trade represents a 22.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

• On Wednesday, September 2nd, Phillips Courtney sold 1,981 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $52,437.07.

Maze Therapeutics Trading Up 1.3%

Shares of NASDAQ:MAZE traded up $0.34 during mid-day trading on Friday, reaching $26.21. The stock had a trading volume of 273,266 shares, compared to its average volume of 637,671. The firm has a 50 day simple moving average of $28.74 and a two-hundred day simple moving average of $31.20. Maze Therapeutics, Inc. has a twelve month low of $14.27 and a twelve month high of $53.65. The firm has a market cap of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). On average, research analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. raised its stake in shares of Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the period. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth about $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics during the second quarter worth about $122,983,582. BlackRock Inc. bought a new position in shares of Maze Therapeutics during the second quarter worth about $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics during the second quarter worth about $101,764,000.

Analyst Upgrades and Downgrades

MAZE has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $66.00.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.